APA (7th ed.) Citation

Horn, L., Gettinger, S., Camidge, D. R., Smit, E. F., Janjigian, Y. Y., Miller, V. A., . . . Groen, H. J. (2017). Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer (01695002), 113, 51. https://doi.org/10.1016/j.lungcan.2017.08.014

Chicago Style (17th ed.) Citation

Horn, Leora, et al. "Continued Use of Afatinib with the Addition of Cetuximab After Progression on Afatinib in Patients with EGFR Mutation-positive Non-small-cell Lung Cancer and Acquired Resistance to Gefitinib or Erlotinib." Lung Cancer (01695002) 113 (2017): 51. https://doi.org/10.1016/j.lungcan.2017.08.014.

MLA (9th ed.) Citation

Horn, Leora, et al. "Continued Use of Afatinib with the Addition of Cetuximab After Progression on Afatinib in Patients with EGFR Mutation-positive Non-small-cell Lung Cancer and Acquired Resistance to Gefitinib or Erlotinib." Lung Cancer (01695002), vol. 113, 2017, p. 51, https://doi.org/10.1016/j.lungcan.2017.08.014.